MARKET

OPNT

OPNT

Opiant Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.82
+0.27
+1.99%
Closed 16:00 06/17 EDT
OPEN
13.29
PREV CLOSE
13.55
HIGH
13.88
LOW
13.22
VOLUME
25.91K
TURNOVER
--
52 WEEK HIGH
14.98
52 WEEK LOW
6.79
MARKET CAP
59.85M
P/E (TTM)
-19.0279
1D
5D
1M
3M
1Y
5Y
Opiant Pharmaceuticals: Return On Capital Employed Insights
During Q1, Opiant Pharmaceuticals's (NASDAQ:OPNT) reported sales totaled $6.39 million. Despite a 152.19% in earnings, the company posted a loss of $2.32 million. In Q4, Opiant Pharmaceuticals brought in $9.92 million in sales but lost $920.52 thousand in ...
Benzinga · 06/03 15:11
Opiant Pharmaceuticals to Present at the 2021 Jefferies Virtual Healthcare Conference
SANTA MONICA, Calif., May 24, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, announced today that its Chief Executive Officer, Dr. R...
GlobeNewswire · 05/24 20:05
Opiant Pharmaceuticals to Hold Virtual 2021 Annual Shareholder Meeting on Tuesday, June 15, 2021 at 9:00am PDT
Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, announced today that, due to the continuing public health concerns relating to the coronavirus (COVID-19)...
GlobeNewswire · 05/18 20:05
OPNT: PK and PD Trials for OPNT003 Underway…
By David Bautz, PhD NASDAQ:OPNT READ THE FULL OPNT RESEARCH REPORT
Benzinga · 05/13 15:41
8-K: OPIANT PHARMACEUTICALS, INC.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 05/12 00:24
BRIEF-Opiant Pharmaceuticals Q1 Loss Per Share $0.66
reuters.com · 05/11 21:22
Opiant Pharmaceuticals: Q1 Earnings Insights
Shares of Opiant Pharmaceuticals (NASDAQ:OPNT) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share fell 65.00% over the past year to ($0.66), which beat the estimate of ($0.71).
Benzinga · 05/11 20:47
Opiant Pharmaceuticals Says Based On Mid-Range Of FY21 Guidance For Sales Of NARCAN Says Continues To See FY21 Royalty Revenue From Sale Of NARCAN Nasal Spray Of ~$27.8M
Based on the mid-range of the full-year 2021 guidance for sales of NARCAN® Nasal Spray provided by EBS, of $315 million, we continue to expect full-year 2021 royalty revenue from the sale of
Benzinga · 05/11 20:46
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of OPNT. Analyze the recent business situations of Opiant Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average OPNT stock price target is 41.33 with a high estimate of 44.00 and a low estimate of 38.00.
EPS
Institutional Holdings
Institutions: 46
Institutional Holdings: 1.15M
% Owned: 26.47%
Shares Outstanding: 4.33M
TypeInstitutionsShares
Increased
5
33.68K
New
5
15.33K
Decreased
9
39.67K
Sold Out
3
2.60K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.60%
Pharmaceuticals & Medical Research
+0.27%
Key Executives
Chairman/Director
Craig Collard
President/Chief Executive Officer/Director
Roger Crystal
Chief Financial Officer
David O'Toole
Executive Vice President
Arvind Agrawal
Chief Scientific Officer
Phil Skolnick
General Counsel
Rahsaan Thompson
Other
Aziz Mottiwala
Director
Ann MacDougall
Director
Gabrielle Silver
Director
Thomas Thomas
Independent Director
Richard Daly
Independent Director
Lorianne Masuoka
No Data
About OPNT
Opiant Pharmaceuticals, Inc. is a specialty pharmaceutical company developing medicines for addictions and drug overdose. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdose. The Company’s pipeline includes medicines in development for Opioid Overdose Reversal (OOR), Alcohol Use Disorder (AUD), Opioid Use Disorder (OUD), and Acute Cannabinoid Overdose (ACO). The Company also is focused on other treatment opportunities within the addiction and drug overdose field.

Webull offers kinds of Opiant Pharmaceuticals Inc stock information, including NASDAQ:OPNT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OPNT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OPNT stock methods without spending real money on the virtual paper trading platform.